Literature DB >> 9971814

Identification of retroviral late domains as determinants of particle size.

L Garnier1, L J Parent, B Rovinski, S X Cao, J W Wills.   

Abstract

Retroviral Gag proteins, in the absence of any other viral products, induce budding and release of spherical, virus-like particles from the plasma membrane. Gag-produced particles, like those of authentic retrovirions, are not uniform in diameter but nevertheless fall within a fairly narrow distribution of sizes. For the human immunodeficiency virus type 1 (HIV-1) Gag protein, we recently reported that elements important for controlling particle size are contained within the C-terminal region of Gag, especially within the p6 sequence (L. Garnier, L. Ratner, B. Rovinski, S.-X. Cao, and J. W. Wills, J. Virol. 72:4667-4677, 1998). Deletions and substitutions throughout this sequence result in the release of very large particles. Because the size determinant could not be mapped to any one of the previously defined functions within p6, it seemed likely that its activity requires the overall proper folding of this region of Gag. This left open the possibility of the size determinant residing in a subdomain of p6, and in this study, we examined whether the late domain (the region of Gag that is critical for the virus-cell separation step) is involved in controlling particle size. We found that particles of normal size are produced when p6 is replaced with the totally unrelated late domain sequences from Rous sarcoma virus (contained in its p2b sequence) or equine infectious anemia virus (contained in p9). In addition, we found that the large particles released in the absence of p6 require the entire CA and adjacent spacer peptide sequences, whereas these internal sequences of HIV-1 Gag are not needed for budding (or proper size) when a late domain is present. Thus, it appears the requirements for budding are very different in the presence and absence of p6.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9971814      PMCID: PMC104476     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences.

Authors:  L E Henderson; M A Bowers; R C Sowder; S A Serabyn; D G Johnson; J W Bess; L O Arthur; D K Bryant; C Fenselau
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.

Authors:  H G Göttlinger; T Dorfman; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

3.  Biological techniques for avian sarcoma viruses.

Authors:  E Hunter
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

4.  Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src.

Authors:  J W Wills; R C Craven; R A Weldon; T D Nelle; C R Erdie
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

5.  Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly.

Authors:  R C Craven; R P Bennett; J W Wills
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

6.  Functional domains of HIV-1 gag-polyprotein expressed in baculovirus-infected cells.

Authors:  M Royer; M Cerutti; B Gay; S S Hong; G Devauchelle; P Boulanger
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

7.  Incorporation of chimeric gag protein into retroviral particles.

Authors:  R A Weldon; C R Erdie; M G Oliver; J W Wills
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

8.  Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector.

Authors:  V Karacostas; K Nagashima; M A Gonda; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

9.  Ubiquitin in avian leukosis virus particles.

Authors:  D Putterman; R B Pepinsky; V M Vogt
Journal:  Virology       Date:  1990-06       Impact factor: 3.616

10.  Creation and expression of myristylated forms of Rous sarcoma virus gag protein in mammalian cells.

Authors:  J W Wills; R C Craven; J A Achacoso
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

View more
  15 in total

1.  Mass determination of rous sarcoma virus virions by scanning transmission electron microscopy.

Authors:  V M Vogt; M N Simon
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Ubiquitin is part of the retrovirus budding machinery.

Authors:  A Patnaik; V Chau; J W Wills
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

Review 3.  Viral late domains.

Authors:  Eric O Freed
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain.

Authors:  M A Accola; B Strack; H G Göttlinger
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Contributions of Charged Residues in Structurally Dynamic Capsid Surface Loops to Rous Sarcoma Virus Assembly.

Authors:  Katrina J Heyrana; Boon Chong Goh; Juan R Perilla; Tam-Linh N Nguyen; Matthew R England; Maria C Bewley; Klaus Schulten; Rebecca C Craven
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

6.  Mapping and characterization of the N-terminal I domain of human immunodeficiency virus type 1 Pr55(Gag).

Authors:  S Sandefur; R M Smith; V Varthakavi; P Spearman
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

7.  Functional roles of equine infectious anemia virus Gag p9 in viral budding and infection.

Authors:  C Chen; F Li; R C Montelaro
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

8.  The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner.

Authors:  Dimiter G Demirov; Jan M Orenstein; Eric O Freed
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

9.  Tsg101 control of human immunodeficiency virus type 1 Gag trafficking and release.

Authors:  A Goff; L S Ehrlich; S N Cohen; C A Carter
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Analysis of bovine leukemia virus gag membrane targeting and late domain function.

Authors:  Huating Wang; Kendra M Norris; Louis M Mansky
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.